Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Branden Camp / AP
The Senate passed the reauthorization of the FDA user fees yesterday by a lopsided vote of 94-1. Who was the one? It was Bernie Sanders, returning to his pre-presidential campaign form as the guy who doesn't care if the army is with him or not.
Why did Sanders vote against it? Because the FDA bill "does nothing to lower drug prices and is a giveaway to the pharmaceutical industry," per his spokesman, Josh Miller-Lewis. (One provision Republican Sen. Susan Collins did cite as a measure against high drug prices: It would require the FDA to speed up the reviews of generic drug applications in markets where there's not a lot of competition.)
What's next: Because the Senate cleared the House version of the FDA bill, it can go straight to Trump's desk. He's expected to sign it into law.